SG11201703313SA - Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production - Google Patents

Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Info

Publication number: SG11201703313SA
Authority: SG; Singapore
Prior art keywords: production; methods; dimeric immunoglobulins; cell retargeting; hetero
Prior art date: 2014-11-04

Application number

SG11201703313SA

Other languages

English (en)

Inventor

Romain Ollier

Samuel Hou

Rami Lissilaa

Darko Skegro

Jonathan Back

Original Assignee

Glenmark Pharmaceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-04

Filing date

2015-11-03

Publication date

2017-05-30

2014-11-04 Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en

2015-11-03 Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa

2017-05-30 Publication of SG11201703313SA publication Critical patent/SG11201703313SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Neurology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Obesity (AREA)
Psychiatry (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG11201703313SA 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production SG11201703313SA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/EP2014/073738 WO2015063339A1 (en)	2013-11-04	2014-11-04	Production of t cell retargeting hetero-dimeric immunoglobulins
EP15167034		2015-05-08
PCT/EP2015/075628 WO2016071355A1 (en)	2014-11-04	2015-11-03	Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Publications (1)

Publication Number	Publication Date
SG11201703313SA true SG11201703313SA (en)	2017-05-30

Family

ID=53059011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201703313SA SG11201703313SA (en)	2014-11-04	2015-11-03	Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Country Status (20)

Country	Link
EP (1)	EP3215541A1 (es)
JP (3)	JP2018501297A (es)
KR (1)	KR102760422B1 (es)
CN (1)	CN107207596A (es)
AU (1)	AU2015341884B2 (es)
BR (1)	BR112017009263A2 (es)
CA (1)	CA2965745C (es)
CL (1)	CL2017001090A1 (es)
CO (1)	CO2017005240A2 (es)
EA (1)	EA039658B1 (es)
HK (1)	HK1244014A1 (es)
IL (1)	IL251848A0 (es)
MA (1)	MA40894A (es)
MX (1)	MX2017005814A (es)
MY (1)	MY186929A (es)
NZ (1)	NZ732019A (es)
PE (1)	PE20171041A1 (es)
PH (1)	PH12017500819A1 (es)
SG (1)	SG11201703313SA (es)
WO (1)	WO2016071355A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
DK2943511T3 (da)	2013-01-14	2019-10-21	Xencor Inc	Nye heterodimeriske proteiner
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
RU2727836C2 (ru)	2013-07-25	2020-07-24	Сайтомкс Терапьютикс, Инк.	Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
AP2016009222A0 (en)	2013-11-04	2016-05-31	Glenmark Pharmaceuticals Sa	Production of t cell retargeting hetero-dimeric immunoglobulins
BR112016022385A2 (pt)	2014-03-28	2018-06-19	Xencor, Inc	anticorpos específicos que se ligam a cd38 e cd3
BR112017001579A2 (pt) *	2014-07-25	2017-11-21	Cytomx Therapeutics Inc	anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
US11773166B2 (en)	2014-11-04	2023-10-03	Ichnos Sciences SA	CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
KR102689285B1 (ko)	2014-11-26	2024-07-31	젠코어 인코포레이티드	Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
CN107406512A (zh)	2014-11-26	2017-11-28	Xencor公司	结合cd3和cd38的异二聚体抗体
TWI796283B (zh)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru)	2015-07-31	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
AU2016365742A1 (en)	2015-12-07	2018-06-21	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and PSMA
HUE060504T2 (hu)	2016-02-03	2023-03-28	Amgen Res Munich Gmbh	PSMA és CD3 bispecifikus T-sejthez kötõ ellenanyag-konstrukciók
US10787518B2 (en)	2016-06-14	2020-09-29	Xencor, Inc.	Bispecific checkpoint inhibitor antibodies
KR20190020341A (ko)	2016-06-28	2019-02-28	젠코어 인코포레이티드	소마토스타틴 수용체 2에 결합하는 이종이량체 항체
SG11201909498XA (en) *	2017-04-24	2019-11-28	Glenmark Pharmaceuticals Sa	T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
CN110691789A (zh) *	2017-06-05	2020-01-14	努玛治疗有限公司	新型抗cd3抗体
WO2018224441A1 (en) *	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-cd3 antibodies
WO2018224682A1 (en)	2017-06-08	2018-12-13	Tusk Therapeutics Ltd	Cd38 modulating antibody
WO2018224683A1 (en) *	2017-06-08	2018-12-13	Tusk Therapeutics Ltd	Cd38 modulating antibody
UY37757A (es) *	2017-08-10	2018-11-30	Grifols Diagnostic Solutions Inc	Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante
AU2018316521B2 (en)	2017-08-16	2025-01-30	Black Belt Therapeutics Limited	CD38 modulating antibody
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11236173B2 (en)	2017-08-16	2022-02-01	Black Belt Therapeutics Limited	CD38 antibody
US11542338B2 (en)	2017-08-16	2023-01-03	Black Belt Therapeutics Limited	CD38 modulating antibody
BR112020007309A2 (pt)	2017-10-14	2020-09-29	Cytomx Therapeutics, Inc.	anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
AU2018366199A1 (en)	2017-11-08	2020-05-28	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
AU2019247415A1 (en)	2018-04-04	2020-10-22	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
EP3856347A1 (en) *	2018-09-25	2021-08-04	Ichnos Sciences SA	Antibody quantification in biological samples
KR102353568B1 (ko) *	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
EP3914616A1 (en)	2019-01-23	2021-12-01	Encefa	Cd31 competitors and uses thereof
WO2020182984A2 (en) *	2019-03-13	2020-09-17	Ichnos Sciences SA	Non-consensus glycosylation of bispecific antibodies
WO2020237173A1 (en) *	2019-05-23	2020-11-26	VelosBio Inc.	Anti-ror1/anti-cd3 bispecific binding molecules
WO2020250940A1 (ja) *	2019-06-11	2020-12-17	小野薬品工業株式会社	免疫抑制剤
CN110551222B (zh) *	2019-08-27	2023-06-06	重庆市畜牧科学院	一种新型双功能抗体及其用途
CN112538114B (zh) *	2019-09-20	2025-05-02	上海普铭生物科技有限公司	抗人cd38抗体及其应用
TWI841790B (zh) *	2019-09-30	2024-05-11	大陸商和鉑醫藥（上海）有限責任公司	靶向cd3的抗體、雙特異性抗體及其用途
CN113493519B (zh) *	2020-03-19	2022-12-27	浙江道尔生物科技有限公司	一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2021185003A1 (zh)	2020-03-19	2021-09-23	深圳纽迪瑞科技开发有限公司	压力感应式结构及电子产品
CN115803340A (zh) *	2020-04-24	2023-03-14	纪念斯隆凯特琳癌症中心	抗cd3抗体及其用途
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CN115916824A (zh) *	2020-06-17	2023-04-04	Y-单克隆抗体制药有限公司	用于人类疾病治疗的cd38抗体
KR20230166150A (ko)	2020-08-19	2023-12-06	젠코어 인코포레이티드	항-cd28 조성물
WO2022192403A1 (en)	2021-03-09	2022-09-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
EP4380631A4 (en) *	2021-08-04	2025-06-25	Abpro Corporation	Cd3 targeting antibodies and uses thereof
CN118108852B (zh) *	2023-11-23	2025-11-18	浙江大学	一种抗啶虫脒单克隆抗体及其重组全长IgG表达质粒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2541436T3 (es) *	2004-02-06	2015-07-20	Morphosys Ag	Anticuerpos humanos anti-CD38 y usos para ellos
MX2007011064A (es) *	2005-03-23	2008-02-19	Genmab As	Anticuerpos contra cd38 para tratamiento de mieloma multiple.
AR055191A1 (es) *	2005-10-12	2007-08-08	Morphosys Ag	Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
EP1914242A1 (en) *	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
SI2975051T1 (sl) *	2009-06-26	2021-08-31	Regeneron Pharmaceuticals, Inc.	Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
PL2522724T3 (pl) *	2009-12-25	2020-07-13	Chugai Seiyaku Kabushiki Kaisha	Sposób modyfikowania polipetydów do oczyszczania multimerów polipeptydowych
JP6093696B2 (ja) *	2010-06-09	2017-03-08	ゲンマブエー／エス	ヒトｃｄ３８に対する抗体
JOP20210044A1 (ar) *	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
SG10201602371VA (en) *	2011-03-25	2016-04-28	Glenmark Pharmaceuticals Sa	Hetero-dimeric immunoglobulins
HK1215950A1 (zh) *	2012-09-25	2016-09-30	艾科诺斯科技股份有限公司	异源二聚免疫球蛋白的纯化
EP2914302B1 (en) *	2012-11-05	2017-01-04	MorphoSys AG	Radiolabelled antibody and uses thereof
AP2016009222A0 (en) *	2013-11-04	2016-05-31	Glenmark Pharmaceuticals Sa	Production of t cell retargeting hetero-dimeric immunoglobulins

2015
- 2015-11-02 MA MA040894A patent/MA40894A/fr unknown
- 2015-11-03 CA CA2965745A patent/CA2965745C/en active Active
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/es unknown
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/es unknown
- 2015-11-03 KR KR1020177015252A patent/KR102760422B1/ko active Active
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/en not_active Ceased
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 HK HK18103440.0A patent/HK1244014A1/zh unknown
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 EA EA201790961A patent/EA039658B1/ru unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/pt not_active Application Discontinuation
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/en not_active Withdrawn
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/ja active Pending
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/zh active Pending
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/es unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/es unknown
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/ja active Pending
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/ja active Active

Also Published As

Publication number	Publication date
CA2965745C (en)	2023-12-05
EP3215541A1 (en)	2017-09-13
CN107207596A (zh)	2017-09-26
MX2017005814A (es)	2017-08-02
MY186929A (en)	2021-08-26
IL251848A0 (en)	2017-06-29
EA039658B1 (ru)	2022-02-22
CA2965745A1 (en)	2016-05-12
PH12017500819A1 (en)	2017-10-02
KR102760422B1 (ko)	2025-02-03
AU2015341884A1 (en)	2017-06-08
PE20171041A1 (es)	2017-07-19
JP2019214582A (ja)	2019-12-19
EA201790961A1 (ru)	2017-10-31
JP7403505B2 (ja)	2023-12-22
CO2017005240A2 (es)	2017-10-31
HK1244014A1 (zh)	2018-07-27
AU2015341884B2 (en)	2020-09-17
KR20170078831A (ko)	2017-07-07
JP2021184722A (ja)	2021-12-09
WO2016071355A1 (en)	2016-05-12
BR112017009263A2 (pt)	2018-01-30
JP2018501297A (ja)	2018-01-18
MA40894A (fr)	2017-09-12
CL2017001090A1 (es)	2018-01-05
NZ732019A (en)	2022-07-29

Publication	Publication Date	Title
IL251848A0 (en)	2017-06-29	Hetero-dimeric immunoglobulins targeting cd3/cd38 t cells and methods for their production
DK3237005T3 (en)	2024-11-18	Bispecific tetravalent antibodies and methods of making and using thereof
ZA201603433B (en)	2019-03-27	Production of t cell retargeting hetero-dimeric immunoglobulins
IL255406B (en)	2021-09-30	A method for growing in the culture of Acramansia
PT3268390T (pt)	2025-01-13	Métodos de purificação de anticorpos biespecíficos
IL248007A0 (en)	2016-11-30	Bispecific antibodies that bind to cd38 and cd3
IL256086A (en)	2018-02-28	Anti-her2 antibodies and methods of use
SG11201606575TA (en)	2016-09-29	Method of producing polyethylene and polyethylene thereof
SG11201705293WA (en)	2017-07-28	Methods of making chimeric antigen receptor-expressing cells
IL257411A (en)	2018-04-30	Improved production of immunoglobulins
PL3453721T3 (pl)	2022-11-07	Sposób wytwarzania aneksyny v
ZA201700525B (en)	2020-08-26	Method of synthetic fuel gas production
IL248697A0 (en)	2017-01-31	Methods for purifying antibodies
IL250451A0 (en)	2017-03-30	Anti-vasa antibodies, and methods for their preparation and use
PL3140392T3 (pl)	2023-11-27	Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
GB201608060D0 (en)	2016-06-22	Method of culturing T cells
IL252712A0 (en)	2017-08-31	Method for protein production
GB201411430D0 (en)	2014-08-13	Method of producing metallic tanralum
SG11201609269TA (en)	2016-12-29	Method of culturing cells
PT3194599T (pt)	2020-12-18	Método para produção de células modificadas que expressam hox e células modificadas obtidas pelo método